Stockscreener 앱 받기
59.04
0.84%
-0.50
시간 외 거래:
59.04
전일 마감가:
$59.54
열려 있는:
$58.85
하루 거래량:
637.03K
Relative Volume:
0.68
시가총액:
$2.58B
수익:
$535.08M
순이익/손실:
$-48.27M
주가수익비율:
-52.09
EPS:
-1.1335
순현금흐름:
$-31.54M
1주 성능:
+0.65%
1개월 성능:
-6.20%
6개월 성능:
-8.52%
1년 성능:
+52.09%
1일 변동 폭
$57.32
$59.33
1주일 범위
$57.09
$61.37
52주 변동 폭
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
명칭
Tarsus Pharmaceuticals Inc
전화
(949) 409-9820
주소
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
59.04 | 2.62B | 535.08M | -48.27M | -31.54M | -1.1335 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-11-20 | 개시 | Mizuho | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-27 | 재개 | H.C. Wainwright | Buy |
| 2023-11-20 | 개시 | Goldman | Neutral |
| 2023-07-18 | 개시 | William Blair | Outperform |
| 2023-05-18 | 개시 | Guggenheim | Buy |
| 2022-08-01 | 개시 | Barclays | Overweight |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-23 | 개시 | Oppenheimer | Outperform |
| 2020-11-10 | 개시 | BofA Securities | Buy |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Ladenburg Thalmann | Buy |
| 2020-11-10 | 개시 | Raymond James | Strong Buy |
모두보기
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Tarsus Pharmaceuticals Inc (TARS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Midday Stock Roundup: Rivian Automotive Up on Piper Sandler Upgrade - Orange County Business Journal
Tarsus Pharmaceuticals Inc (TARS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tarsus Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:TARS - TradingView
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching (TARS) - Seeking Alpha
Tarsus Pharmaceuticals Inc (TARS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Cash Flow - TradingKey
TradingKey - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Institutional Confidence - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tarsus Pharmaceuticals, Inc. (TARS) Options Chain - Yahoo! Finance Canada
TARS|Tarsus Pharmaceuticals Inc|Price:60.100|Chg%:+1.440 - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TARS Maintained by Guggenheim -- Price Target Lowered to $89.00 - GuruFocus
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $89 - Moomoo
How Tarsus Pharmaceuticals Inc. (TARS) Affects Rotational Strategy Timing - Stock Traders Daily
Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 By Investing.com - Investing.com Canada
Tarsus Pushes into Retinal Market in $75M Deal - Orange County Business Journal
Tarsus Pharmaceuticals commercial chief leaves company - MSN
Tarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks Continue - Yahoo Finance
Tarsus acquires iRenix Medical, adds late-stage ocular antiseptic - Glance by Eyes On Eyecare
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS) - The Globe and Mail
Tarsus Pharmaceuticals Announces Executive Leadership Transition - VisionMonday.com
Tarsus Chief Commercial Officer Departs - Orange County Business Journal
Tarsus Pharmaceuticals acquires iRenix for $75 million upfront By Investing.com - Investing.com Nigeria
A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $90 to $100 - Moomoo
Tarsus Pharmaceuticals, Inc. Announces Management Changes, Effective July 13, 2026 - marketscreener.com
Tarsus Pharmaceuticals Announces Chief Commercial Officer Transition - TipRanks
Tarsus Pharmaceuticals Hits Day Low of $57.51 Amid Price Pressure - MarketsMojo
Tarsus Pharmaceuticals (TARS) Announces Departure of Chief Comme - GuruFocus
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth - The Manila Times
[8-K] Tarsus Pharmaceuticals, Inc. Reports Material Event - Stock Titan
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline - TradingView
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo
Tarsus Pharmaceuticals Acquires iRenix Medical, Developer of Late-Stage Ocular Antiseptic IRX-101 - VisionMonday.com
All you need to know about Tarsus Pharmaceuticals (TARS) rating upgrade to buy - MSN
Tarsus Pharmaceuticals Acquires iRenix for $75M - Orange County Business Journal
TARS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $88 - GuruFocus
Tarsus Pharmaceuticals (TARS) Q3 2024 earnings summary - Quartr
Tarsus Pharmaceuticals (TARS) Slips 1.5% as Stock Holds Above Key SupportSector Neutral Pair - dars.gov.et
Tarsus Pharmaceuticals, Inc. (TARS) iRenix Medical, Inc.,M&A CallSlideshow (NASDAQ:TARS) 2026-07-09 - Seeking Alpha
Tarsus Pharmaceuticals (TARS) M&A announcement Summary - Quartr
Tarsus Pharmaceuticals (TARS) Acquires iRenix Medical for $75M - GuruFocus
Tarsus Pharmaceuticals acquires iRenix for $75 million upfront - Investing.com
Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101 - MSN
TARS Acquires iRenix Medical for $75M in a Strategic Move - GuruFocus
Tarsus Pharmaceuticals Buys IRenix Medical - Moomoo
Tarsus Pharmaceuticals Acquires iRenix With $37.5M Cash, Stock; Milestones Up to $490M - TradingView
Tarsus (NASDAQ: TARS) acquires iRenix, adds late-stage IRX-101 eye asset - Stock Titan
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 - GlobeNewswire
Tarsus Pharmaceuticals Inc (TARS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tarsus Pharmaceuticals Inc 주식 (TARS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Farrow Jeffrey S | See Remarks |
Jun 16 '26 |
Sale |
60.95 |
14,396 |
877,436 |
56,801 |
| Goodrich Katherine | Director |
Jun 15 '26 |
Sale |
62.08 |
2,954 |
183,384 |
2,233 |
| LINK WILLIAM J PHD | Director |
Jun 15 '26 |
Sale |
62.12 |
12,500 |
776,495 |
106,786 |
2.44%
0.02%
자본화:
|
볼륨(24시간):